Based on the association of SMARCA4 expression with poor clinical outcome, and observations that SMARCA4 knock-down leads to a significant decrease in PCa cell growth in line with previous studies33,34, we posited that a SMARCA4 knock-down signature (composed of genes deregulated upon SMARCA4 depletion) would be associated with more indolent PCa. The gene discussed is SMARCA4; the disease is posterior cortical atrophy.